Company: SXTPW
Filing Date: 2025-08-15
Form Type: PRE 14A
Source: 0001213900-25-077435
Chunk: 41

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-15
Form: PRE 14A
Chunk 41
---
 which we are or will be a participant
to determine if they are in the best interests of our stockholders and the Company. Transactions, arrangements or relationships or any
series of similar transactions, arrangements or relationships in which a related person had or will have a material interest and that
exceed $120,000 are subject to the Audit Committee’s review. Any member of the Audit Committee who is a related person with respect
to a transaction under review may not participate in the deliberation or vote respecting approval or ratification of the transaction.

Related persons are directors, director nominees,
executive officers, holders of 5% or more of our voting stock and their immediate family members. Immediate family members are spouses,
parents, stepparents, children, stepchildren, siblings, daughters-in-law, sons-in-law and any person, other than a tenant or domestic
employee, who resides in the household of a director, director nominee, executive officer or holder of 5% or more of our voting stock.
After its review, the Audit Committee may approve or ratify the transaction.

Other than as disclosed below, and except for
the regular salary and bonus payments made to our directors and officers in the ordinary course of business as described in the section
“Executive Compensation,” there have been no transactions since January 1, 2023 or any currently proposed transaction
or series of similar transactions to which the Company was or is to be a party, in which the amount involved exceeds USD$120,000 and in
which any current or former director or officer of the Company, any 5% or greater stockholder of the Company or any member of the immediate
family of any such persons had or will have a direct or indirect material interest.

<div align='center'>23

PROPOSAL 2</div>

APPROVAL OF AN AMENDMENT TO INCREASE THE NUMBER OF AUTHORIZED SHARES UNDER THE 2022 EQUITY INCENTIVE PLAN BY 250,000 SHARES

Our Board has adopted a resolution declaring it
advisable and in the best interests of the Company and its stockholders that the shares of common stock authorized for issuance under
the 2022 Plan be increased by 250,000 (the “Plan Amendment”).

On November 22, 2022,
our Board and our stockholders approved the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The 2022 Plan governs equity
awards to our employees, directors, officers, consultants